Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide License, Collaboration Agreement on CSF1R Antibody Program

Loading...
Loading...
Bristol-Myers Squibb Company
BMY
and Five Prime Therapeutics, Inc.
FPRX
today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime's colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies' existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor types. "By blocking a key mediator of immunosuppression in the tumor
See full press release
Posted In: NewsContractsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...